<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00227461</url>
  </required_header>
  <id_info>
    <org_study_id>AMBarrett1</org_study_id>
    <secondary_id>none applicable</secondary_id>
    <nct_id>NCT00227461</nct_id>
  </id_info>
  <brief_title>Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.</brief_title>
  <official_title>Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kessler Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kessler Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates the possibility that levetiracetam may improve the symptoms of chronic
      post-stroke aphasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the study, 50 post-stroke subjects with aphasia will take levetiracetam and we will
      evaluate their speech, language, and memory in an ABAB design.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2005</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Speech and language assessment</measure>
    <time_frame>6 months - 1year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Memory assessment</measure>
    <time_frame>6 months to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Aphasia</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Wait control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Levitiracetam is started after a delay, with dosage and administration as described below.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levitiracetam is started immediately after baseline data is collected; dosage and administration as described below.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Wait first, then levetiracetam</intervention_name>
    <description>Levetiracetam 250 mg orally twice daily for 7 days. This will increase to 500 mg oral twice daily for 7 days the following week. If this dose is tolerated, it will then be increased to 750 mg orally twice daily for another 7 days and then increased to 1000 mg orally twice daily for 7 days.</description>
    <arm_group_label>Treatment first</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam first, then wait</intervention_name>
    <description>subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design</description>
    <arm_group_label>Wait control</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stroke

          -  Aphasia

          -  Can give consent

        Exclusion Criteria:

          -  Renal failure

          -  Pregnancy

          -  Other neurological condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A.M. Barrett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kessler Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kessler Foundation</name>
      <address>
        <city>West Orange</city>
        <state>New Jersey</state>
        <zip>07052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 26, 2005</study_first_submitted>
  <study_first_submitted_qc>September 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2005</study_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kessler Foundation</investigator_affiliation>
    <investigator_full_name>A. M. Barrett, MD</investigator_full_name>
    <investigator_title>Director, Stroke Rehabilitation Research</investigator_title>
  </responsible_party>
  <keyword>Aphasia</keyword>
  <keyword>Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Aphasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levetiracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

